Singapore markets closed

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.69+0.09 (+1.61%)
At close: 04:00PM EDT
5.63 -0.06 (-1.05%)
After hours: 07:37PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 466.25M
Enterprise value -214.74M
Trailing P/E 43.08
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)2.13
Price/book (mrq)0.71
Enterprise value/revenue -0.95
Enterprise value/EBITDA -8.72

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-87.24%
S&P500 52-week change 3-16.62%
52-week high 346.91
52-week low 35.31
50-day moving average 37.57
200-day moving average 37.20

Share statistics

Avg vol (3-month) 3452.6k
Avg vol (10-day) 3621.61k
Shares outstanding 583.26M
Implied shares outstanding 6N/A
Float 869.33M
% held by insiders 19.11%
% held by institutions 170.25%
Shares short (14 Sept 2022) 42.3M
Short ratio (14 Sept 2022) 45.64
Short % of float (14 Sept 2022) 43.65%
Short % of shares outstanding (14 Sept 2022) 42.77%
Shares short (prior month 14 Aug 2022) 42.75M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 6.90%
Operating margin (ttm)10.92%

Management effectiveness

Return on assets (ttm)1.96%
Return on equity (ttm)2.47%

Income statement

Revenue (ttm)224.99M
Revenue per share (ttm)2.71
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)184.16M
Net income avi to common (ttm)15.53M
Diluted EPS (ttm)0.13
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)684.48M
Total cash per share (mrq)8.22
Total debt (mrq)3.5M
Total debt/equity (mrq)0.53
Current ratio (mrq)27.46
Book value per share (mrq)7.93

Cash flow statement

Operating cash flow (ttm)-131.01M
Levered free cash flow (ttm)-140.2M